What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

This article will reflect on the compensation paid to John Melki who has served as CEO of Genetic Signatures Limited (ASX:GSS) since 2011. This analysis will also evaluate the appropriateness of CEO compensation when taking into account the earnings and shareholder returns of the company.

View our latest analysis for Genetic Signatures

Advertisement

How Does Total Compensation For John Melki Compare With Other Companies In The Industry?

Our data indicates that Genetic Signatures Limited has a market capitalization of AU$281m, and total annual CEO compensation was reported as AU$564k for the year to June 2020. We note that's an increase of 44% above last year. In particular, the salary of AU$308.1k, makes up a huge portion of the total compensation being paid to the CEO.

On examining similar-sized companies in the industry with market capitalizations between AU$130m and AU$518m, we discovered that the median CEO total compensation of that group was AU$564k. This suggests that Genetic Signatures remunerates its CEO largely in line with the industry average. Moreover, John Melki also holds AU$2.2m worth of Genetic Signatures stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

Component20202019Proportion (2020)SalaryAU$308kAU$292k55%OtherAU$256kAU$99k45%Total CompensationAU$564k AU$390k100%

Talking in terms of the industry, salary represented approximately 77% of total compensation out of all the companies we analyzed, while other remuneration made up 23% of the pie. It's interesting to note that Genetic Signatures allocates a smaller portion of compensation to salary in comparison to the broader industry. If salary is the major component in total compensation, it suggests that the CEO receives a higher fixed proportion of the total compensation, regardless of performance.

ceo-compensation
ASX:GSS CEO Compensation January 18th 2021

Genetic Signatures Limited's Growth

Genetic Signatures Limited has seen its earnings per share (EPS) increase by 1.6% a year over the past three years. Its revenue is up 98% over the last year.

It's great to see that revenue growth is strong. Combined with modest EPS growth, we get a good impression of the company. So while we'd stop short of saying growth is absolutely outstanding, there are definitely some clear positives! Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

Has Genetic Signatures Limited Been A Good Investment?

Boasting a total shareholder return of 497% over three years, Genetic Signatures Limited has done well by shareholders. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

In Summary...

As we noted earlier, Genetic Signatures pays its CEO in line with similar-sized companies belonging to the same industry. However, the company's EPS growth numbers over the last three years is not that impressive. At the same time, shareholder returns have remained strong over the same period. We would like to see EPS growth from the business, although we wouldn't say the CEO compensation is high.

Whatever your view on compensation, you might want to check if insiders are buying or selling Genetic Signatures shares (free trial).

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

If you’re looking to trade Genetic Signatures, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About ASX:GSS

Genetic Signatures

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Flawless balance sheet and fair value.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0776.3% undervalued
83 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
YA
SOFI logo
Yang_ on SoFi Technologies ·

SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System

Fair Value:US$22.9820.4% undervalued
8 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
KO
CSL logo
Kouj on CSL ·

CSL: The Dip Is the Opportunity

Fair Value:AU$1556.7% undervalued
6 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
GA
DHT logo
GavrielH on DHT Holdings ·

DHT Holdings, inc: Strait of Hormuz Risk Amidst US-Israel vs Iran Tensions Spikes VLCC Rates.

Fair Value:US$3648.3% undervalued
2 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

AS
BFIT logo
ashwin3407 on Basic-Fit ·

Basic-Fit: Why the Market Is Mispricing Europe’s Largest Low-Cost Gym Operator

Fair Value:€68.4756.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CF
CFFF
DRO logo
CFFF on DroneShield ·

DroneShield's Growth Will Drive Revenue Up by 25.39% Amidst New Success

Fair Value:AU$1.36195.6% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VE
Vestra
PATH logo
Vestra on UiPath ·

UiPath Inc. (PATH): Agentic AI Pivot and Milestone Profits Set the Stage for Q4 Results

Fair Value:US$19.6841.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

KA
NU logo
kabz2342 on Nu Holdings ·

Nu holdings will continue to disrupt the South American banking market

Fair Value:US$64.376.9% undervalued
51 users have followed this narrative
3 users have commented on this narrative
27 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59631.9% undervalued
1306 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0227.0% undervalued
1102 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative